Fibrosis Risk Factors and Serum Noninvasive Fibrosis Markers in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Ngā tūemi rite

• The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease
  mā: Clément J. F. Heymann, me ētahi atu.
  I whakaputaina: (2024-12-01)
• Integrated plasma metabolomics and lipidomics profiling highlight distinctive signatures with hashimoto’s thyroiditis
  mā: Guoqiang Wang, me ētahi atu.
  I whakaputaina: (2025-07-01)
• Complementary approach for analysis of phospholipids by liquid chromatography hyphenated to elemental and molecular mass spectrometry
  mā: Christian Vosse, me ētahi atu.
  I whakaputaina: (2020-06-01)
• Novel eicosanoid signature in plasma provides diagnostic for metabolic dysfunction-associated steatotic liver disease
  mā: Oswald Quehenberger, me ētahi atu.
  I whakaputaina: (2024-10-01)
• Lipidome Changes Associated with a Diet-Induced Reduction in Hepatic Fat among Adolescent Boys with Metabolic Dysfunction-Associated Steatotic Liver Disease
  mā: Helaina E. Huneault, me ētahi atu.
  I whakaputaina: (2024-03-01)